Clinical Trial Update: Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating etidronate for arterial calcifications due to CD73 deficiency (ACDC) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arterial Calcification
• Cd73 Deficiency

Drugs mentioned

• Etidronate (etidronate disodium)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Arterial Calcification, CD73 Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2022-10-04